<DOC>
	<DOCNO>NCT02777736</DOCNO>
	<brief_summary>Comparison cumulative incidence CNS relapse patient diffuse large B-cell lymphoma intermediate high risk CNS relapse treat CNS prophylaxis : either 2 dos intravenous methotrexate 3g/m2 i.v . ( arm A ) 6 dos intrathecal methotrexate 12mg ( arm B ) patient low risk CNS relapse without CNS prophylaxis ( arm C ) .</brief_summary>
	<brief_title>CNS Prophylaxis Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Patients diffuse large B-cell lymphoma evaluate risk factor CNS relapse initial staging ( age &gt; 60years , lactate dehydrogenase ( LDH ) &gt; reference range , clinical stage III/IV , performance status accord Eastern Cooperative Oncology Group ( ECOG ) &gt; 1 , kidney and/or adrenal gland involvement , involvement &gt; 1 extranodal organ ) include evaluation cerebrospinal fluid . All patient systemic DLBCL without CNS involvement treat systemic chemotherapy : either 6 cycle R CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednison ) +2xR ( rituximab ) 6 cycle DA EPOCH R ( dose adjust etoposide , prednison , vincristin , cyclophosphamide , doxorubicin ) +2xR ( rituximab ) . Patients â‰¥ 2 risk factor CNS relapse occult meningeal involvement randomize 1:1 ratio either arm A 2 cycle prophylactic methotrexate 3g/m2 i.v. , arm B prophylactic 6x intrathecal methotrexate 12mg ( 1x intrathecal methotrexate cycle systemic chemotherapy ) . Patients 0-1 risk factor allocate arm C without CNS prophylaxis . Patients observe CNS relapse follow-up 1year end first-line treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>histologically confirm DLBCL age 1872 year sign informed consent study firstline treatment 6 cycle R CHOP +2x R 6 cycle DA EPOCH R+ 2xR DLBCL concomitant initial CNS involvement PMBL ( primary mediastinal Bcell lymphoma ) treatment another chemotherapy R CHOP DA EPOCH R HIV positive , active hepatitis B C concomitant serious disease ( base decision physicianinvestigator ) noncompliance patient contraindication application anthracycline base chemotherapy high dose methotrexate pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Lymphoma , B cell</keyword>
	<keyword>Central nervous system relapse</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Intrathecal chemotherapy</keyword>
</DOC>